183 related articles for article (PubMed ID: 35513519)
1. Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis.
Cui L; Xia W; Yu C; Dong S; Pei Y
Arch Osteoporos; 2022 May; 17(1):74. PubMed ID: 35513519
[TBL] [Abstract][Full Text] [Related]
2. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Eldecalcitol for Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Liu H; Wang G; Wu T; Mu Y; Gu W
Front Endocrinol (Lausanne); 2022; 13():854439. PubMed ID: 35518938
[TBL] [Abstract][Full Text] [Related]
4. Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials.
Xu Z; Fan C; Zhao X; Tao H
Drug Des Devel Ther; 2016; 10():509-17. PubMed ID: 26869769
[TBL] [Abstract][Full Text] [Related]
5. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation.
Jiang Y; Tang H; Ma X; Cheng Q; Lin H; Jin X; Zhang Z; Yu W; He S; Kobayashi T; Uehara S; Matsumoto T; Xia W
J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis.
Zheng Z; Luo J
J Orthop Surg Res; 2020 Sep; 15(1):390. PubMed ID: 32907639
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
[TBL] [Abstract][Full Text] [Related]
8. Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients.
Mukaiyama K; Uchiyama S; Nakamura Y; Ikegami S; Taguchi A; Kamimura M; Kato H
Tohoku J Exp Med; 2015 Dec; 237(4):339-43. PubMed ID: 26639092
[TBL] [Abstract][Full Text] [Related]
9. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.
Matsumoto T; Ito M; Hayashi Y; Hirota T; Tanigawara Y; Sone T; Fukunaga M; Shiraki M; Nakamura T
Bone; 2011 Oct; 49(4):605-12. PubMed ID: 21784190
[TBL] [Abstract][Full Text] [Related]
10. Eldecalcitol: a review of its use in the treatment of osteoporosis.
Sanford M; McCormack PL
Drugs; 2011 Sep; 71(13):1755-70. PubMed ID: 21902297
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Suzuki T; Nakamura Y; Tanaka M; Kamimura M; Ikegami S; Uchiyama S; Kato H
Mod Rheumatol; 2018 Mar; 28(2):376-379. PubMed ID: 28397581
[TBL] [Abstract][Full Text] [Related]
12. Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials.
Yang C; Le G; Lu C; Wei R; Lan W; Tang J; Zhan X
Medicine (Baltimore); 2020 Feb; 99(7):e19042. PubMed ID: 32049802
[TBL] [Abstract][Full Text] [Related]
13. Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT.
Ito M; Nakamura T; Fukunaga M; Shiraki M; Matsumoto T
Bone; 2011 Sep; 49(3):328-34. PubMed ID: 21605716
[TBL] [Abstract][Full Text] [Related]
14. Eldecalcitol, an Active Vitamin D
Takeda S; Saito M; Sakai S; Yogo K; Marumo K; Endo K
Calcif Tissue Int; 2017 Oct; 101(4):433-444. PubMed ID: 28624935
[TBL] [Abstract][Full Text] [Related]
15. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
16. Alendronate for the Treatment of Osteoporosis in Men: A Meta-Analysis of Randomized Controlled Trials.
Xu Z
Am J Ther; 2017; 24(2):e130-e138. PubMed ID: 27058577
[TBL] [Abstract][Full Text] [Related]
17. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
18. Eldecalcitol for the treatment of osteoporosis.
Matsumoto T; Endo I
Drugs Today (Barc); 2012 Mar; 48(3):189-96. PubMed ID: 22462038
[TBL] [Abstract][Full Text] [Related]
19. Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis.
Hagino H; Takano T; Fukunaga M; Shiraki M; Nakamura T; Matsumoto T
J Bone Miner Metab; 2013 Mar; 31(2):183-9. PubMed ID: 23129180
[TBL] [Abstract][Full Text] [Related]
20. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
